



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
[www.uspto.gov](http://www.uspto.gov)

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/898,416	07/03/2001	Catherine Dulac	0575/48557-A/JPW/ADM	1905
7590	11/19/2003		[REDACTED]	[REDACTED] EXAMINER PAK, MICHAEL D
			[REDACTED] ART UNIT 1646	[REDACTED] PAPER NUMBER

DATE MAILED: 11/19/2003

Please find below and/or attached an Office communication concerning this application or proceeding.

Kc

<b>Office Action Summary</b>	<b>Application No.</b>	<b>Applicant(s)</b>
	09/898,416	DULAC ET AL.
	<b>Examiner</b>	<b>Art Unit</b>
	Michael Pak	1646

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --  
**Period for Reply**

**A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.**

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

**Status**

- 1) Responsive to communication(s) filed on 04 August 2003.
- 2a) This action is FINAL.                    2b) This action is non-final.
- 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

**Disposition of Claims**

- 4) Claim(s) 29-32 and 96-99 is/are pending in the application.
- 4a) Of the above claim(s) 29-32 is/are withdrawn from consideration.
- 5) Claim(s) \_\_\_\_\_ is/are allowed.
- 6) Claim(s) 96-99 is/are rejected.
- 7) Claim(s) \_\_\_\_\_ is/are objected to.
- 8) Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

**Application Papers**

- 9) The specification is objected to by the Examiner.
- 10) The drawing(s) filed on \_\_\_\_\_ is/are: a) accepted or b) objected to by the Examiner.  
 Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
 Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

**Priority under 35 U.S.C. §§ 119 and 120**

- 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).  
 a) All    b) Some \* c) None of:  
 1. Certified copies of the priority documents have been received.  
 2. Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.  
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- \* See the attached detailed Office action for a list of the certified copies not received.
- 13) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application) since a specific reference was included in the first sentence of the specification or in an Application Data Sheet. 37 CFR 1.78.  
 a) The translation of the foreign language provisional application has been received.
- 14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121 since a specific reference was included in the first sentence of the specification or in an Application Data Sheet. 37 CFR 1.78.

**Attachment(s)**

- 1) Notice of References Cited (PTO-892)
- 2) Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) Information Disclosure Statement(s) (PTO-1449) Paper No(s) A, B.
- 4) Interview Summary (PTO-413) Paper No(s). \_\_\_\_\_
- 5) Notice of Informal Patent Application (PTO-152)
- 6) Other: \_\_\_\_\_

### **DETAILED ACTION**

1. Applicant's election with traverse of group III, claims 96-99, drawn to VN1, in Paper filed 4 August 2003 is acknowledged.

The traversal is on the ground(s) that claims of the groups I-IX are not independent and distinct. This is not found persuasive because the claims of group III-IX are unconnected in design, operation, or effect because they are drawn to products having different structures and functions. Claims of Group I are drawn to a method whereas the claims of group II are drawn to a transgenic mouse. Furthermore, the traversal is on the ground(s) that there would not be a serious burden on the examiner if restriction were not required. However, the search of the claims require the search in different classifications. Furthermore, the search of the nucleic acids of groups III-IX requires searching each sequence against a large number of sequence databases and any nucleic acid sequences regardless of kingdom or phylum of the organism such as plants.

The requirement is still deemed proper and is therefore made FINAL.

### ***Specification***

2. The amendment filed 3 July 2001 is objected to under 35 U.S.C. 132 because it introduces new matter into the disclosure. 35 U.S.C. 132 states that no amendment shall introduce new matter into the disclosure of the invention. The added material which is not supported by the original disclosure is as follows. The amendment to page

19 by addition of the paragraph is new matter. The specification does not disclose the generic structure with the specific amino acid substitutions.

Applicant is required to cancel the new matter in the reply to this Office Action.

***Claim Rejections - 35 USC § 101***

35 U.S.C. 101 reads as follows:

Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title.

3. Claims 96-99 are rejected under 35 U.S.C. 101 because the claimed invention is not supported by either a substantial asserted utility or a well established utility.

The claims are directed to nucleic acid which encodes a putative orphan pheromone receptor and its variants and fragments. The claimed nucleic acid encoding the polypeptides do not have well established utility because G-protein coupled receptors with similar homology have different functions and the a skilled artisan would have to determine the function of the receptor. The specification on page 5 disclose the asserted utility of using the protein to provide insight into the chemical nature of the pheromones. However, there is no nexus between the claimed protein and the therapeutics for humans' innate behavior. The specification as filed does not disclose or provide evidence that points to a property of the claimed protein such that another non-asserted utility would be well established. The claimed polypeptides do not substantial utility because the skilled artisan would need to prepare, isolate, and analyze the protein in order to determine its function and use. Therefore, the invention is not in readily available form. The polypeptide lacks substantial utility because further

research to identify or reasonably confirm a “real world” context of use is required. Thus, the asserted utility lacks substantial and specific utility because further research to identify or reasonably confirm a “real world” context of use is required. *Brenner V. Manson* 383 U.S. 519, 535-536, 148 USPQ 689, 696 (1966) stated that “Congress intended that no patents be granted on an chemical compound whose sole “utility” consists of its potential role as an object of use-testing … a patent is not a hunting license.” *Brenner* further states that “It is not a reward for the search, but compensation for its successful conclusion.” Any utility of the nucleic acid encoding the protein or other specific asserted utility is directly dependent on the function of the protein. A circular assertion of utility is created where the utility of the protein is needed to break out the circular assertion of utility. The polypeptides do not substantial utility because the skilled artisan would need to prepare, isolate, and analyze the protein in order to determine its functional nexus with human therapeutics. Therefore, the invention is not in readily available form. Instead, further experimentation of the protein itself would be required before it could be used. The disclosed use for the nucleic acid molecule of the claimed invention is generally applicable to any nucleic acid and therefore is not particular to the nucleic acid sequence claimed. The claims directed to vectors and host cells do not have utility because the nucleic acid without utility is needed to practice the inventions.

Claims 96-99 also rejected under 35 U.S.C. 112, first paragraph. Specifically, since the claimed invention is not supported by either a substantial asserted utility or a

well established utility for the reasons set forth above, one skilled in the art clearly would not know how to use the claimed invention.

***Claim Rejections - 35 USC § 112***

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

4. Claims 96-99 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claims 96-98 encompass the consecutive amino acid sequence which are separated by multiple fragments with the terms "or" which is confusing because the fragments are not the same size.

Claim 99 is indefinite because the claims are drawn to non-elected groups.

5. Claims 96-98 are rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention. This is a new matter rejection and a written description rejection.

Claims 96-98 encompass a subgenus of pheromone receptor with specific amino acid description or substitution. The specification does not disclose the claimed subgeneric pheromone receptor. The specification discloses the species with specific SEQ ID NO: or generic pheromone receptor but not the subgeneric limitation. Claims 96-98 encompass a genus with a large number of nucleic acid molecules whose sequence cannot be envisioned because the claimed nucleic acids are directed comprising language. The essential feature of the claimed nucleic acid molecule is drawn to the orphan receptor whose function is not known because the ligand is not known. One of skilled in the art cannot envision the nucleic acid molecules or the gene comprising the particular sequence. The claims encompass nucleic acid molecule encoding variants whose structure is not known or nucleic acid molecules encoding other variant proteins with different function from SEQ ID NO:8 taught in the specification. Claimed nucleic acid encoding protein variants encompass a large genus of proteins which are alleles or variants whose function has yet to be identified from different species of animal because the structure of the newly identified naturally occurring protein is not known. *University of California v. Eli Lilly and Co.* (CAFC) 43 USPQ2d 1398 held that a generic claim to human or mammalian when only the rat protein sequence was disclosed did not have written description in the specification.

6. Claims 96-99 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the enablement requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to enable one skilled in the art to

which it pertains, or with which it is most nearly connected, to make and/or use the invention.

The determination of whether undue experimentation is needed is based on examining the factors summarized *In re Wands*, 858 F.2d 731, 8 USPQ2d 1400 (Fed. Cir. 1988).

Breadth of the claims. The claims 96-98 encompass an isolated nucleic acid encoding an analog, variant, and fragments of a pheromone receptor, and vectors comprising the nucleic acid thereof, because the specification on page 19, lines 16-27, describe a nucleic acid encoding a pheromone receptor to include molecules encoding for polypeptide analog or molecules coding for fragments or derivatives of antigenic polypeptides which differ from naturally-occurring forms in terms of the identity or location of one or more amino acid residues and which share some or all properties of naturally-occurring forms. Claim 99 is drawn to the specific sequence.

The amount of direction of guidance provided. The specification provides guidance in making an orphan G-protein receptor. However, no positive results have been provided showing the ligand which bind the receptors.

The presence or absence of working examples of the invention. The specification provides working examples of how to make and isolated rat nucleic acid molecules of SEQ ID NO:2 which encode the VN1receptors of SEQ ID NO: 8. However, no positive results have been provided showing the ligand which bind the receptors. No working example of isolated nucleic acid molecule encoding pheromone receptors from any other species from mammals or vertebrates.

The nature of the invention. The nature of the invention is recombinant cloning of cDNA encoding G-protein coupled receptors in the vomeronasal glands using polymerase chain reaction with oligonucleotides designed from conserved regions of G-protein receptors. Invention also provide tissue specific hybridization with the probes prepared based on the sequence of the cDNA isolated.

The state of the prior art. The state of the prior art at the time of the invention was such that one skilled in the art has isolated nucleic acids encoding putative odorant receptors found in the olfactory epithelium and the odorant receptors belong to a family of G-protein coupled receptors based on structural similarity (Buck et al.(U), page 180, figure 5). The state of the art is silent with respect to an isolated nucleic acid molecules encoding pheromone receptors. The state of the art is such that one skilled in the art have shown that steroids such as 16-androstenes, estrenes, and androstenols are pheromones for humans, but the pheromones are species specific (Berliner(B), columns 1-3). At the time of the invention, receptors which bind steroids belong to the family of steroid receptors, and the estrogen receptor and androgen receptor which belong to the steroid receptor family have no structural or functional relationship with G-protein coupled receptors (Wang et al.(V), page 165, figure 4; Buck et al.(U), page 180, figure 5). Steroid receptors are DNA binding proteins whereas the G-protein coupled receptors are seven transmembrane receptors (Wang et al.(V), page 165, figure 4; Buck et al.(U), page 180, figure 5). The state of the art is silent with respect to a G-protein coupled receptor which binds 16-androstenes, estrenes, or androstenols. The specification fails to provide guidance or working examples to isolate nucleic acids

encoding pheromone receptors which bind androstenes or estrenes. Furthermore, the specification fails to provide any ligands for the pheromone receptors. Even after the filing date of the invention, the state of the art indicate that no ligand is known for the pheromone receptors isolated recombinantly (Ryba et al.(W), page 375, second column, second paragraph). Furthermore, even after the filing date of the invention, the state of the art is such that chemicals that act as pheromones are largely uncharacterized (Ryba et al.(W), page 371, first column, last sentence). The state of the art is such that it is not uncommon to isolate orphan receptors where the ligand for the receptors are unknown thus lacking any type of binding assays with the receptor (Watson et al.(X), pages 223-230).

The quantity of experimentation necessary. The state of the art is silent with respect to the relationship of vomeronasal organ in vertebrates outside the mammalian species. For example, in order to make a cDNA library from vomeronasal organ from other vertebrate species from other classes such as lampreys(agnatha-jawless fish), sharks(chondrichthyes-catilaginous fish), marlins(osteichthyes-bony fish), salamanders(amphibians), eagles(birds), and crocodiles(reptiles), one skilled in the art would have to establish phylogenetic relationship of the vomeronasal organ with these other species structurally and functionally. Such determination would require, finding, analyzing, and determining the organs a homologous in evolutionary relationship by showing some type of structural similarity by dissection or microscopy. Once the structural relationship has been established for the phylogenetic relationship of the vomeronasal organ, then functional relationship has to be established showing

pheromonal response to some pheromone and behavior. It should be noted that pheromones for most of the vertebrate species are not known, thus necessitating an empirical determination of the pheromones for many of these species. Assuming that the isolated nucleic acid encoding the naturally occurring pheromone receptor has been identified, since the claims encompass analogs, variants, and fragments, one would test with the ligand the binding to these pheromone receptors. If we take variants only, and using only the naturally occurring 20 amino acids and assuming we use VN1 which has 315 amino acids, then the number of experimentation is 315 to the 20th power which is  $9 \times 10^{49}$  number of experiments to determine whether the variants for VN1 are functional.

The predictability and unpredictability. The state of the art discussed immediately above indicate that one skilled in the art could not practice the claimed invention of making and using isolated nucleic acid encoding a pheromone receptor where the pheromone receptors can be analogs, variants, or fragments. The specification fails to provide guidance or working examples to isolate nucleic acids encoding pheromone receptors which bind androstenes or estrenes because state of the art indicated such steroids bind receptors belonging to family of steroid receptors and not G-protein coupled receptors. Furthermore, orphan receptors without any known ligands such as the pheromone receptors cannot be tested with variants and fragments because without ligand one of skill in the art cannot determine the function of the pheromone receptor using binding assays. One skilled in the art would have to empirically test chemical compounds to determine whether the ligand binds the orphan receptors.

In view of the extent and the unpredictability of the experimentation required to practice the invention as claimed, one skilled in the art could not make the invention without undue experimentation.

***Priority***

7. Applicant's claim for domestic priority under 35 U.S.C. 119(e) and 120 is acknowledged. However, the continuing application upon which priority is claimed fails to provide adequate support under 35 U.S.C. 112 for the claimed invention.

***Claim Rejections - 35 USC § 102***

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(a) the invention was known or used by others in this country, or patented or described in a printed publication in this or a foreign country, before the invention thereof by the applicant for a patent.

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

(e) the invention was described in (1) an application for patent, published under section 122(b), by another filed in the United States before the invention by the applicant for patent or (2) a patent granted on an application for patent by another filed in the United States before the invention by the applicant for patent, except that an international application filed under the treaty defined in section 351(a) shall have the effects for purposes of this subsection of an application filed in the United States only if the international application designated the United States and was published under Article 21(2) of such treaty in the English language.

(e) the invention was described in a patent granted on an application for patent by another filed in the United States before the invention thereof by the applicant for patent, or on an international application by another who has fulfilled the requirements of paragraphs (1), (2), and (4) of section 371(c) of this title before the invention thereof by the applicant for patent.

The changes made to 35 U.S.C. 102(e) by the American Inventors Protection Act of 1999 (AIPA) and the Intellectual Property and High Technology Technical Amendments Act of 2002 do not apply when the reference is a U.S. patent resulting directly or indirectly from an international application filed before November 29, 2000. Therefore, the prior art date of the reference is determined under 35 U.S.C. 102(e) prior to the amendment by the AIPA (pre-AIPA 35 U.S.C. 102(e)).

8. Claims 96-99 are rejected under 35 U.S.C. 102(b) as being anticipated by Dulac et al. (Cell, 1995).

Dulac discloses nucleic acid encoding a pheromone receptor which is 100% identical to the claimed SEQ ID NO:8. Burgess discloses vectors and host cells and method of making recombinant protein using the host cell.

9. No claims are allowed.

10. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Michael Pak, whose telephone number is (703) 305-7038. The examiner can normally be reached on Monday through Friday from 8:30 AM to 2:00 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Yvonne Eyler, can be reached on (703) 308-6564.

The fax phone number for the organization where this application or proceeding is assigned is (703) 872-9306.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-1235.

Art Unit: 1646

*Michael D. Pak*  
Michael Pak  
Primary Patent Examiner  
Art Unit 1646  
14 November 2003